Fund's performance carries a high cost I won't quibble with the investment performance celebrated ( quot;A quiet top gun, Sept. 21), but it's telling -- and frankly sad -- that the way Ed Owens  quot;beat the market quot; for 20 years was with a fund  quot;dominated by investments in big pharmaceutical companies. quot;